Anfield Capital Management LLC Takes $50,000 Position in Quince Therapeutics, Inc. (NASDAQ:QNCX)

Anfield Capital Management LLC purchased a new position in Quince Therapeutics, Inc. (NASDAQ:QNCX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 26,656 shares of the company’s stock, valued at approximately $50,000. Anfield Capital Management LLC owned about 0.06% of Quince Therapeutics at the end of the most recent quarter.

Separately, Geode Capital Management LLC increased its position in Quince Therapeutics by 24.2% in the 3rd quarter. Geode Capital Management LLC now owns 339,125 shares of the company’s stock worth $263,000 after purchasing an additional 66,170 shares during the last quarter. Institutional investors and hedge funds own 30.75% of the company’s stock.

Quince Therapeutics Stock Up 4.3 %

Shares of Quince Therapeutics stock opened at $1.45 on Friday. Quince Therapeutics, Inc. has a 12-month low of $0.51 and a 12-month high of $2.45. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. The stock has a 50 day moving average price of $1.63 and a two-hundred day moving average price of $1.34. The stock has a market capitalization of $63.80 million, a P/E ratio of -1.17 and a beta of 0.61.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on QNCX shares. Brookline Capital Management began coverage on Quince Therapeutics in a report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price target for the company. Maxim Group assumed coverage on shares of Quince Therapeutics in a research report on Thursday, November 7th. They issued a “buy” rating and a $6.00 target price for the company. Finally, D. Boral Capital restated a “buy” rating and set a $12.00 price target on shares of Quince Therapeutics in a research note on Wednesday, February 5th. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Quince Therapeutics has an average rating of “Buy” and a consensus price target of $9.50.

Quince Therapeutics Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.